Joint Ventures Reduce the Risk of Major Capital Investments
Harvard Business Review
APRIL 6, 2016
Building a large-scale biopharmaceutical facility requires up to $500 million. The latest nuclear reactor designs, promising higher safety, longer operating life, and lower operating costs, cost up to $25 billion after factoring in the huge budget overruns. This all presents CEOs with a tough dilemma. Dual asymmetrical joint venture.
Let's personalize your content